WARREN, N.J., Nov. 30, 2011 (GLOBE NEWSWIRE) — MonoSol Rx, LLC (“MonoSol Rx”), the developer of PharmFilm(r) drug delivery technology and a drug delivery company specializing in film pharmaceutical products, announced that the U.S. Food and Drug Administration (FDA) has listed MonoSol Rx’s U.S. Patent No. 8,017,150 in the Orange Book for the Suboxone(r) (buprenorphine HCl and naloxone HCl dihydrate) sublingual film products. (Source: Medical News (via PRIMEZONE))
MonoSol Rx Announces Listing of Patent in FDA Orange Book for Suboxone(R) Sublingual Films
Previous post: Cost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care
Next post: Compensation Effects on Clinical Trial Data Collection in Opioid-Dependent Young Adults.
